arXiv Science⌕ Search
Home/Archive/arXiv

arXiv · 2305.06076

The price elasticity of Gleevec in patients with Chronic Myeloid Leukemia enrolled in Medicare Part D: Evidence from a regression discontinuity design

Samantha E. Clark·Ruth Etzioni·Jerry Radich·Zachary Marcum·Anirban Basu
View original source ↗Read source document ↗Export metadata ↓

Abstract

Objective To assess the price elasticity of branded imatinib in chronic myeloid leukemia (CML) patients on Medicare Part D to determine if high out-of-pocket payments (OOP) are driving the substantial levels of non-adherence observed in this population. Data sources and study setting We use data from the TriNetX Diamond Network (TDN) United States database for the period from first availability in 2011 through the end of patent exclusivity following the introduction of generic imatinib in early 2016. Study design We implement a fuzzy regression discontinuity design to separately estimate the effect of Medicare Part D enrollment at age 65 on adherence and OOP in newly-diagnosed CML patients initiating branded imatinib. The corresponding price elasticity of demand (PED) is estimated and results are assessed across a variety of specifications and robustness checks. Data collection/extraction methods Data from eligible patients following the application of inclusion and exclusion criteria were analyzed. Principal findings Our analysis suggests that there is a significant increase in initial OOP of $232 (95% Confidence interval (CI): $102 to $362) for individuals that enrolled in Part D due to expanded eligibility at age 65. The relatively smaller and non-significant decrease in adherence of only 6 percentage points (95% CI: -0.21 to 0.08) led to a PED of -0.02 (95% CI: -0.056, 0.015). Conclusion This study provides evidence regarding the financial impact of coinsurance-based benefit designs on Medicare-age patients with CML initiating branded imatinib. Results indicate that factors besides high OOP are driving the substantial non-adherence observed in this population and add to the growing literature on PED for specialty drugs.

Explore related subjects

econ.EMstat.AP

Keep this discovery

BibTeXRIS

Samantha E. Clark, Ruth Etzioni, Jerry Radich, Zachary Marcum, Anirban Basu. 2023-05-10. The price elasticity of Gleevec in patients with Chronic Myeloid Leukemia enrolled in Medicare Part D: Evidence from a regression discontinuity design. https://arxiv.org/abs/2305.06076

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related papers

arXiv2026

Identification in Linear Quantile Panel Models

This paper studies identification in linear quantile panel models with unrestricted individual heterogeneity when the number of time periods is fixed and small. We impose strict exogeneity, whereby the conditional quantile restriction holds given the individual's complete regressor history and latent individual effect, but otherwise allow the disturbances to be arbitrarily dependent over time.

econ.EM↗
arXiv2026

Experimental Design for Policy Choice

We show how to optimally design experiments when the resulting data will be used to choose a welfare-maximizing policy subject to constraints. A decision maker seeks to maximize Bayes expected welfare by choosing a policy whose effects depend on an unknown finite-dimensional parameter. The decision maker has access to a first wave of experimental data with a fixed design but may choose the design of a second wave that will be collected before choosing the policy. The resulting experimental design--policy choice problem is a very high-dimensional dynamic program that is generally intractable in finite samples. We propose a tractable approximation based on the limit experiment and show it is asymptotically optimal using a new asymptotic representation theorem for adaptive experiments with continuous treatments. We apply the method to a conditional cash transfer experiment and demonstrate the potential for large gains from tailoring the experiment to the policy choice.

econ.EM↗
arXiv2026

Designing Spatial Treatments

Spatial treatments are interventions assigned to locations potentially distinct from those of the responding units. We study their optimal design under a general model in which a unit's response diminishes with distance to a treated site. Our estimand of interest is an ``uncontaminated'' effect equal to the average impact of a single intervention site over all hypothetical sites. We propose a novel design based on a Mat\'{e}rn point process which separates treatments by a distance of at least $r$. A larger choice of $r$ reduces bias by separating interventions but increases variance by reducing their numerosity. We choose $r$ to maximize the rate of convergence of a Horvitz-Thompson estimator and prove that this is minimax rate-optimal. We provide weak conditions under which the estimator is asymptotically normal and propose a variance estimator.

econ.EM↗